Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients
Umamaheswar Duvvuri(City University of New York), Julie E. Bauman(George Washington University), Diego Alvarado(Unknown), Veronique Neumeister(Yale University), Theresa LaVallee(Achillion Pharmaceuticals (United States)), Jennifer R. Grandis(University of California, San Francisco), Seungwon Kim(UPMC Hillman Cancer Center), Thomas Hawthorne(Celldex Therapeutics (United States)), Richard Gedrich(Arvinas (United States)), Jonathan George(University of California, San Francisco), Ahmed Chenna
Cited by 42
Related Papers
Head and neck squamous cell carcinoma
|Nature Reviews Disease Primers|2020|4k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590